Local crops offer cost-effective alternative to treat severe child malnutrition in Kenya

Across Kenya's driest regions, more than 2.7 million people are running out of food. Among them are hundreds of thousands of children whose bodies are shutting down from malnutrition—a condition that demands immediate, specialized treatment. The standard remedy exists: a high-energy paste called ready-to-use therapeutic food, or RUTF. But it rarely reaches the children who need it most. A new study suggests the reason may be simpler to solve than anyone expected: the recipe itself.

Researchers from the Hebrew University of Jerusalem, working with teams across Israel, Kenya, Nigeria, Ireland, and the United Kingdom, have developed an alternative formulation using crops that grow locally in Kenya—chickpeas, sorghum, maize, and soybeans. They call it ChSMS. In preclinical testing, it outperformed the conventional therapeutic food that relies on imported powdered milk and peanuts. The plant-based version delivered 14 percent of its energy from protein, compared with 10 percent in the commercial product. Its protein-quality score reached 87 percent against 69 percent for the standard formulation. More tellingly, it supported better recovery from malnutrition in test conditions, including catch-up growth—the body's ability to regain lost development.

The barrier to treating malnutrition globally is not mystery or complexity. It is cost and access. Current therapeutic foods reach only about 30 percent of children who need them worldwide. Powdered milk, the ingredient that anchors most formulations, must be imported to Kenya at considerable expense. That dependence creates a fragile supply chain: when prices spike or shipments delay, treatment programs stall. Lower-income countries struggle to expand access because they cannot absorb the price volatility of imported goods. A locally sourced alternative could break that cycle.

Kenya's crisis is acute and immediate. The Kenya Integrated Food Security Phase Classification estimates that by the end of October 2026, approximately 348,000 people in the arid and semi-arid lands will face emergency levels of food insecurity. Six counties—Mandera, Turkana, Wajir, Garissa, Marsabit, and Tana River—are among the hardest hit. Nationally, roughly 883,000 children between six and fifty-nine months old have acute malnutrition. Of those, 224,300 have the severe form that demands immediate intervention. An additional 117,000 cases of acute malnutrition are projected among pregnant and breastfeeding women and girls between April 2026 and March 2027. The numbers are not abstract: they represent children whose growth is stunted, whose immune systems are compromised, whose futures are being erased by the simple absence of adequate food.

The appeal of the ChSMS formulation extends beyond nutrition. If locally grown crops become the foundation of therapeutic food, agricultural supply chains in Kenya could strengthen. Farmers would have a guaranteed market for their harvest. Treatment programs would reduce their dependence on international suppliers and the price shocks that come with it. The approach addresses malnutrition not as a medical problem alone but as an economic and agricultural one.

Yet the path from laboratory success to clinical reality remains uncertain. The researchers acknowledge that further testing is essential. The formulation has shown promise in preclinical work, but it has not yet been tested in children. Safety must be confirmed. Effectiveness in real-world conditions must be proven. The team, led by Dr. Aurelie Bechoff and professors Efrat Monsonego-Ornan and Ram Reifen, emphasizes that affordability cannot come at the expense of nutritional quality or proven outcomes. The stakes are too high for shortcuts.

What the study does establish is that the conventional approach—importing expensive, milk-based formulations—is not the only path forward. Local crops can deliver superior nutrition at lower cost, if the science holds. For Kenya, where food insecurity is worsening due to poor rainfall and climbing prices, that possibility arrives at precisely the moment it is needed. The next phase is clinical trials—testing the formulation in actual children, in actual communities, under actual conditions. If those trials succeed, the way malnutrition is treated in Kenya, and potentially across the developing world, could shift fundamentally.